How much does a box of domestic ibrutinib cost and cost-effectiveness analysis

Ibrutinib (also known as ibrutinib in China) is a drug used to treat chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) and Waldenstrom's macroglobulinemia (WM) and many other B BTK inhibitors for malignant tumors. The drug has been launched in China and has been included in the medical insurance catalog, allowing patients to purchase drugs through formal channels in hospital pharmacies. The price of domestically produced ibrutinib is about 8,000 yuan per box. Although medical insurance coverage can alleviate the financial burden to a certain extent, the original price is still relatively high, which is not a small burden for patients who need to take the medicine for a long time.

In overseas markets, especially in India, Bangladesh and other places, multiple generic versions of ibrutinib have been launched, with common specifications such as 140mg120 tablets or 140mg112 tablets. The price of Indian generic drugs is relatively close to the people. The price of a box is about 1,000 RMB, which is one-eighth or even lower than the price of domestic original drugs. The version produced by the famous Bangladeshi pharmaceutical company Beacon (Beacon) is slightly more expensive due to production process, brand and distribution channels, about 4000 yuan per box, which is still more than 50% cheaper than the domestic original drug, so it is favored by some patients.

From a cost-effective perspective, overseas generic drugs undoubtedly have more price advantages, especially the Indian version, which can significantly reduce long-term treatment costs. However, domestically produced ibrutinib has been approved by the Chinese Food and Drug Administration, its quality and efficacy are guaranteed, and it can enjoy medical insurance reimbursement, making it the first choice for standardized treatment. In contrast, although the prices of overseas generic drugs are low, they have not been certified by the China Food and Drug Administration, so there are compliance and safety risks in their use, and purchase channels need to be carefully screened. Therefore, patients should weigh multiple factors such as financial ability, doctor's advice, and medication safety when making a choice.

With the gradual expansion of the domesticBTK inhibitor market and the expansion of medical insurance coverage, the domestic selling price of ibrutinib is expected to further decline in the future. In addition, as more domestically produced generic drugs enter the market, price competition may also form, easing the financial pressure on patients. For patients currently in need of medication, it is recommended to give priority to purchasing drugs through domestic channels that can be reimbursed by medical insurance, and to regularly follow up with doctors to evaluate the treatment effect. If you consider purchasing drugs overseas, be sure to obtain the drugs through a formal and qualified platform and use them under the guidance of professional doctors to ensure safety and efficacy.

Reference materials:https://www.drugs.com